BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shenzhen MingSight Relin Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shenzhen MingSight Relin Pharmace
 uticals's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06979076-466@assetmemo.bio
DTSTAMP:20261121T010445Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:MS-553: Phase 1/2 readout est. (NCT06979076)
DESCRIPTION:MS-553\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy: A Ph
 ase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Ref
 ractory or Relapsed CLL/SLL\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ms-553#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06979076
URL:https://assetmemo.bio/drug/ms-553#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
